There was no significant difference between APP/PS1 AD mice treated with CPO_Aβ17–21 P and controls in latency measurements during the radial arm maze testing by two-way ANOVA (p = 0.09 for treatment effect, p = 0.0018 for days effect; data not shown). The gene discussed is APP; the disease is Alzheimer disease.